ArticlePediatric gastroenterology, hepatology & nutrition2026
Diagnostic Utility of Next-Generation Sequencing for Unconjugated Hyperbilirubinemia in Children.
Article in Pediatric gastroenterology, hepatology & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Unconjugated hyperbilirubinemia can cause severe neurologic complications. Next-generation sequencing (NGS) is widely used for molecular diagnosis in pediatric disorders. This study evaluated the clinical features, diagnostic utility of NGS, and prognosis of children with unconjugated hyperbilirubinemia. Methods: Medical records of patients aged <18 years with unconjugated hyperbilirubinemia persisting >3 months from January 2015 to November 2024 were retrospectively reviewed. Hyperbilirubinemia was defined as total bilirubin >1.5 mg/dL. DNA was extracted from blood, and panel-based NGS targeting 96 genes was performed. Results: Among 98 patients, NGS was performed in 30 (30.6%), identifying pathogenic variants in 12 (40.0%). The most frequent diagnosis was Gilbert syndrome (20%), followed by hereditary spherocytosis (16.7%); one patient (3.3%) had Rotor syndrome. Among patients with hereditary spherocytosis, only one showed elevated reticulocyte counts, and none had anemia. Resolution of hyperbilirubinemia occurred in 34 patients (34.7%) with a median duration of 6.6 months. Persistent hyperbilirubinemia >1 year occurred in 35 patients (35.7%), although levels >5 mg/dL were not observed during the maximum follow-up period. Multivariate analysis showed peak bilirubin level (odds ratio, 1.65; 95% confidence interval, 0.087-2.895) was significantly associated with abnormal NGS results. Conclusion: NGS provides effective diagnosis for unconjugated hyperbilirubinemia, with a 40% yield. Hemolytic disease should be considered as an underlying cause, even without anemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.